The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health ...

The history of the DNA-testing startup reads like a checklist of Silicon Valley clichés: founder squabbles, gobs of cash, a ...

Me will pay $30 million and provide three years of security monitoring to settle a lawsuit accusing the genetics testing ...

These days, there are plenty of DNA kits on the market that make the process ... For the average person looking to dig into their genetics and traits, 23andMe is the best DNA test.

Ancestry and genetics-testing company 23andMe has agreed to pay a $30 million settlement after a class-action lawsuit was brought against the company for last year's data breach. The settlement ...

every member of 23andMe's board of directors just resigned — a move that apparently took its ever-optimistic chief executive by surprise. This week, seven of the DNA testing kit company's eight ...

23andMe customers of Chinese and Ashkenazi Jewish origin were allegedly targeted by the hackers, who listed their confidential information for sale on the dark web. Customers using the DNA ...

Genetic testing company 23andMe has agreed to pay $30 million to settle a class action lawsuit from customers impacted by a 2023 data breach when hackers accessed the personal data of millions of ...

NEW YORK (AP) — All of 23andMe's independent directors resigned from its board this week, a rare move that marks the latest challenge for the genetic-testing company. The resignations follow ...

All seven of 23andMe’s independent board members resigned in a stinging rebuke to a proposal by CEO Anne Wojcicki’s plans to to take the company private. Wojcicki, who has been trying to ...

(Reuters) - 23andMe (ME) will pay $30 million and provide ... and posted their information for sale on the dark web. A preliminary settlement of the proposed class action was filed late Thursday ...

23andMe has amassed a vast trove of DNA from its popular test kits and pioneered using genetic information to determine risks for an array of diseases. It became the first firm, in 2017 ...